Neuland Laboratories AGM 2026: ₹34 dividend timeline

AGM date, time, and virtual venue

Neuland Laboratories Limited has scheduled its 42nd Annual General Meeting (AGM) for August 4, 2026 at 10:00 a.m. IST. The meeting will be conducted through Video Conferencing (VC) and Other Audio Visual Means (OAVM). The company has indicated that members can attend the AGM virtually through the NSDL e-Voting system.

The AGM matters for shareholders because key statutory items, including adoption of audited financial statements for FY26, are set to be placed for approval. The company has also put a final dividend proposal on the agenda, which is subject to shareholder approval at the meeting.

Key agenda items shareholders will vote on

The agenda includes adopting the audited financial statements for the financial year 2025-26 (FY26). Alongside the accounts, shareholders will consider the proposal for a final dividend.

Neuland Laboratories’ Board of Directors has recommended a final dividend of ₹34 per equity share (340%) on a face value of ₹10 each for FY26. The company has clarified that the dividend distribution is subject to approval by shareholders at the 42nd AGM.

Final dividend details: amount, record date, and payment timeline

The final dividend recommended is ₹34 per share for FY26. Neuland Laboratories has fixed July 24, 2026 as the record date for determining shareholders eligible to receive the final dividend for the year ended March 31, 2026, pending shareholder approval.

The company has stated that the dividend is payable on or after August 11, 2026, to members whose names appear on the Register of Members as of the record date. It also noted that the dividend will be paid on or after five days from the date of declaration of the final dividend by shareholders at the AGM.

E-voting window and cut-off eligibility

Neuland Laboratories has shared the remote e-voting timeline linked to the AGM. Remote e-voting is scheduled to start on August 1, 2026 at 9:00 a.m. IST and end on August 3, 2026 at 5:00 p.m. IST.

The facility for remote e-voting will be available to members holding shares as of July 28, 2026. Participation, including attending the AGM virtually, will be through the NSDL e-Voting system as communicated by the company.

AGM schedule at a glance

FY26 audit outcome and auditor’s opinion

The company’s Board meeting outcome dated May 12, 2026 stated that audited financial results for FY26 were approved. It also noted an unmodified auditor’s report on the financial statements.

The statutory auditors, M S K A & Associates LLP, Chartered Accountants, issued audit reports with an unmodified opinion, as referenced in the company’s disclosures.

FY26 financial performance: quarterly and annual snapshots

Neuland Laboratories reported strong changes across quarterly and annual metrics in the figures provided.

For Q4FY26, revenue from operations stood at ₹776.25 crore, up 76.54% QoQ from ₹439.71 crore in Q3FY26, and up 136.40% YoY from ₹328.36 crore in Q4FY25. Total income for Q4FY26 was ₹788.71 crore, up 76.14% QoQ from ₹447.76 crore and up 134.86% YoY from ₹335.82 crore in Q4FY25.

Profit after tax (PAT) for Q4FY26 was reported at ₹212.67 crore, up 424.18% QoQ from ₹40.57 crore in Q3FY26 and up 664.85% YoY from ₹27.81 crore in Q4FY25. Separately, standalone PAT for Q4FY26 was ₹212.52 crore, up 425.85% QoQ from ₹40.42 crore and up 666.30% YoY from ₹27.73 crore in Q4FY25.

On an annual basis for FY26, revenue from operations was ₹2,022.99 crore, up 36.98% over ₹1,476.84 crore in FY25. Annual total income was ₹2,053.15 crore for FY26 versus ₹1,497.35 crore in FY25, a 37.12% YoY increase. Consolidated PAT for FY26 was ₹363.99 crore, up 39.94% YoY from ₹260.11 crore, while total comprehensive income for FY26 was ₹365.06 crore compared with ₹260.06 crore in FY25.

Additional period disclosures included in the data

The dataset also lists several income statement metrics across other quarters and periods.

One set of numbers states revenue of ₹4.48 crore versus ₹4.02 crore during Q3FY25 (11% change), EBITDA of ₹0.85 crore versus ₹0.90 crore (-6%), PBT of ₹0.54 crore versus ₹1.28 crore (-57%), and PAT of ₹0.40 crore versus ₹1.01 crore (-60%), along with an EBITDA margin of 19% and PBT margin of 12.1% for Q3FY26.

Another set states total income of ₹516.1 crore compared with ₹315.2 crore during Q2FY25 (63.70% change), EBITDA ₹156.9 crore versus ₹65.7 crore (138.80%), PBT ₹129.0 crore versus ₹48.5 crore (166.60%), and PAT ₹96.5 crore versus ₹32.0 crore (201.60%), with an EBITDA margin of 30.40% for Q2FY26. It also lists total income of ₹300.6 crore compared with ₹444.4 crore during Q1FY25 (-32.40%), EBITDA ₹42.1 crore compared with ₹128.6 crore (-67.30%), with an EBITDA margin of 14.00% for Q1FY26.

The dataset further includes Q1FY25 results for Neuland Laboratories with total income of ₹444.4 crore, a YoY growth of 21.7% versus Q1FY24 (₹365.0 crore) and QoQ growth of 13.8% over Q4FY24 (₹390.4 crore). EBITDA for Q1FY25 was ₹128.6 crore, up 29.5% from Q1FY24 (₹99.3 crore) and up 14.7% from Q4FY24 (₹112.2 crore). H1FY25 highlights included total income of ₹759.6 crore (-3.3% YoY), EBITDA of ₹194.3 crore (-18.9% YoY), EBITDA margin of 25.6% (down 490 bps YoY), and PAT of ₹130.3 crore (-13.9% YoY).

Capacity expansion plan approved by the board

In the May 12, 2026 board meeting outcome, Neuland Laboratories also disclosed a capacity expansion plan at Unit 1. The company plans to expand capacity by 120.5 KL over 12 to 18 months, with an investment of ₹143.4 crore.

Such disclosures are typically followed by closer investor attention on execution timelines and how expansion aligns with recent profitability trends, but the company’s statement in the provided text is limited to scope, time, and capex.

Company and stock details cited in the information

Neuland Laboratories is described as being engaged in manufacturing and selling bulk drugs, catering to domestic and international markets. The provided market snapshot lists a market capitalisation of ₹23,236 crore and a current price of ₹18,087, with a 52-week high/low of ₹19,748 / ₹11,500.

Other figures cited include stock P/E of 63.8, book value of ₹1,461, dividend yield of 0.19%, ROCE of 26.6%, ROE of 21.4%, and face value of ₹10. The same snapshot also notes that promoter holding has decreased over the last three years by 3.50%.

Summary table: key shareholder and financial numbers

What investors should track next

The immediate next step is shareholder voting at the AGM, including approval of the final dividend and adoption of audited financials. Investors tracking the dividend should focus on the record date (July 24, 2026) and the stated payment timeline on or after August 11, 2026.

Separately, the disclosed Unit 1 capacity expansion plan and the audited FY26 results approved by the board provide additional context for how the company is positioning operations after a year in which it reported higher revenue and profit compared with FY25.